WALSH GEORGE J III sold $219K of CHE

WALSH GEORGE J III sold 500 shares of CHEMED CORP (CHE) at $437.83 ($0.22M total) on 2026-05-29.

Original reporting
SEC EDGAR · WALSH GEORGE J III
Published May 29, 2026, 7:42 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 7:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CHE
Neutral
medium confidence
Mentioned
$CHE
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CHENeutralLow
01

Why it matters

This provides incremental sentiment information (insider selling) but lacks new operating/financial catalysts.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a major repricing.

03

What to watch

The transaction is small relative to typical institutional flows; also, the absence of a stated 10b5-1 plan does not by itself confirm intent or timing beyond the disclosed sale.

Relevance 6/10Novelty 6/10Timing: Filed today (2026-05-29) after-hours/late session disclosure window

Background

The article is an SEC Form 4 insider transaction disclosure for Chemed Corp (CHE).

Company-level read

Ticker impact

$CHENeutralMedium confidence
Context

Chemed director George J. Walsh sold 500 shares in an open-market transaction for about $218,915, disclosed via SEC Form 4.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any effect is likely short-lived.

Evidence & confidence

The filing is a disclosed director sale with no 10b5-1 plan stated and no accompanying company-specific operational or financial news.

Market effects

No clear sector read-through from a single director sale without additional company/industry developments.

None.

None.

Counterpoint

Director sales can be routine liquidity/portfolio rebalancing and may not reflect bearish fundamentals, especially without any linkage to company guidance or events.

Key entities

  • CHEMED CORP

    Company whose director disclosed an open-market sale of 500 shares.

  • WALSH GEORGE J III

    Director who sold $218,915 worth of CHE shares on 2026-05-29.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CHEMedAI 9/10

Chemed 3Q 2026: Revenue $690.9M, EPS $5.45— 10-Q Summary

Chemed reported Q3 2026 revenue of $690.9M, up 10.6% YoY, with net income rising 11.5% to $71.6M and EPS increasing 22.2% to $5.45. Growth in VITAS and Roto-Rooter segments drove results, while higher fuel costs pressured margins. The company acquired RotoCo and other franchises, expanding its territories.

$CHEMed

What Chemed (CHE) Said on Its Q3 Earnings Call

Chemed reported Q3 earnings, with Roto-Rooter revenue up 7.5% but EBITDA down 2.5% due to higher costs. Commercial revenue grew 9% to $59.9M, while residential rose 5.2% to $158.8M. The company acquired California franchises for $62.5M, expecting $30M-$35M in 2027 revenue but less than $4M in EBITDA. Chemed repurchased 125,000 shares for $66M. Management expects 2026 EPS to meet or slightly exceed guidance.

$CHEMed

Chemed outlines 12- to 18-month integration timeline for $62.5M California Roto-Rooter franchise buyback while expecting 2026 EPS at or slightly above prior high end (NYSE:CHE)

Chemed (CHE) announced a 12- to 18-month integration timeline for its $62.5M California Roto-Rooter franchise buyback. CEO Kevin McNamara reported VITAS revenue grew 12.2% year-over-year, driven by ADC growth and cost containment. The company expects 2026 EPS to be at or slightly above the prior high end.

$CHEHighAI 8/10

Chemed (CHE) Q3 2026 Earnings Call Transcript

Chemed (CHE) reported Q3 2026 earnings with total revenue up 10.6% and adjusted EPS up 28.1% YoY. VITAS saw 12.2% revenue growth, while Roto Rooter grew 7.5%. Roto Rooter's margins declined due to higher marketing costs and fuel expenses, but acquisitions are expected to drive long-term growth. The company has $229M in cash flow from operations, enabling strategic acquisitions and share repurchases.

$CHEHighAI 8/10

Why is Chemed stock surging today?

Chemed (CHE) stock rose 9.2% after Q3 earnings beat estimates, with adjusted EPS of $6.75 and revenue of $690.9M. VITAS hospice division showed strong growth. Jefferies upgraded the stock to Buy, raising its price target to $620. Bank of America also increased its target to $555. The stock hit a 52-week high.